Pharmaceutical Solutions Provider Skila - Launches iAdvocate - Targeted to Improve the Management of Opinion Leader Relationships
Morris Plains, NJ, February 9, 2005 - Skila, A Sela2
Company, announces the launch of iAdvocate, a new, unique method for managing
pharmaceutical key opinion leader relationships.
The average pharmaceutical brand invests over $38 million on thought leader
development. Pharmaceutical companies are vitally interested in more effective
methods to manage these important relationships. Current methods focus
mainly on simply mapping thought leader influence and building a database
to store that information.
iAdvocate enables the management of key opinion leaders initiatives across
three critical phases: planning, executing and measuring results. By combining
both management and workflow tools, all stake holders can access information
and effectively manage the process to insure a high impact. iAdvocate
utilizes Skila's proprietary Intelligration® platform which integrates
and prioritizes multiple data sources into a "Single Touch Point."
This provides access to critical business data at key points in the decision
making process. Intelligration also provides the communication and workflow
backbone necessary to develop high performance teams. High performance
teams that are more agile and more efficient have greater potential to
drive effectiveness gains.
iAdvocate also incorporates a unique methodology that enables the management
of thought leaders across several important objective parameters including
influence and advocacy. iAdvocate aims to rapidly grow advocacy levels
by optimizing execution, developing and quickly implementing best practices,
and continuously monitoring performance so that companies can quickly
adjust to the continuously changing marketplace. iAdvocate, by providing
a working platform for both management and scientific liaisons, creates
a seamless working environment acutely focused on key objectives and opportunities.
iAdvocate is also easily configurable to adapt to the individual requirements
of each customers unique process.
"We are very excited how iAdvocate can transform the management of
thought leader relationships for our pharmaceutical partners," commented
Moish Tov, CEO of Skila. "Our mission is to provide best in class
solutions that enable pharmaceutical companies to uniquely respond to
today's critical business challenges. We feel that iAdvocate can give
pharmaceutical companies a strategic and competitive advantage in this
critical area."
About Skila
Skila, a BelHealth investment company, is a global technology and services company specializing in fully managed "Solution" as-a-Service (SaaS) product launch lifecycle management and engagement / relationship management solutions for the healthcare industry. Skila’s solutions address the broad needs of global marketing, medical, market access, executive and alliance management teams that include a unique methodology, robust technology and key continuous services for effectively managing global product launches, key opinion leader relationships, market access / managed care, business performance, competitive intelligence, and key partnerships and alliances.
Having developed strong relationships with a broad number of global pharmaceutical companies, Skila’s solutions have been deployed in 61 countries, supporting numerous global brands and more than 10 million user interactions. Skila’s long-standing commitment and understanding of customers’ needs has resulted in the exponential growth and adoption of our methodology, technology and continuous services as the business platform of choice for our clients.
BelHealth is a private healthcare investment fund. For more info, visit www.belhealth.com.
